News

Exicure reported 2025 results that underscore a high-stakes pivot and a narrowing runway. Cash and equivalents fell to $3.7...

Journey Medical reported full-year 2025 revenue of $61.9 million, up 10% year over year, propelled by the April commercial...

Maze Therapeutics reported positive topline results from its Phase 2 HORIZON study of MZE829 in patients with broad APOL1-mediated...

BioCardia reported 2025 results and a slate of regulatory and clinical milestones that could pull cardiac cell therapy back...

PDS Biotechnology will host a March 30 webcast to report 2025 results and provide a clinical and corporate update...

Sellas Life Sciences signaled a catalyst-heavy 2026, reporting year-end 2025 financials while positioning two late-stage AML programs for pivotal...

Alumis has delivered positive Phase 3 topline results for envudeucitinib, its highly selective oral TYK2 inhibitor, in moderate-to-severe plaque...

electroCore posted record 2025 revenue of $32.0 million, up 27% year over year, and guided to approximately 30% growth...

Relmada Therapeutics reported 12-month phase 2 results for NDV-01 in non-muscle invasive bladder cancer showing a 95% complete response...

Financière de Tubize, the reference shareholder of UCB, posted a 2025 profit of €93.2 million, up 3.5% year over...